I think their best short term option with Biosynthesis is to license the process to a company that's selling pure CBD oil to undercut the cost of growing plant. There won't be much market for the other cannabinoids until more research is done and drugs are developed (i.e. the demand becomes real). Bioinformatics, on the other hand, might be useful to other pharmaceutical companies if they can prove success at finding cures and/or treatments.
Unless/until we see a surprise announcement in these areas, the pps will probably bounce between $.20 to $.30/share until we get closer to clinical trials (probably early next year). Long term patience is the key to this stock. JMO
Market Data 
Markets 
AI
